Scarica l'app Stockscreener
6.88
0.15%
0.010
Dopo l'orario di chiusura:
6.90
0.02
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Verastem Inc Borsa (VSTM) Ultime notizie
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Ends Lung Cancer Trial, Reallocates Resources - Sahm
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN
Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada
Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks
Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter
Verastem (VSTM) Halts Development of Avutometinib/Defactinib Com - GuruFocus
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM) - Seeking Alpha
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch - ts2.tech
Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Verastem Oncology (VSTM) Shifts Focus to Promising KRAS G12D Inh - GuruFocus
Calkins, Verastem CFO, sells $628 in shares By Investing.com - Investing.com South Africa
Verastem Oncology provides update on Ramp 203 phase 1/2 clinical trial - marketscreener.com
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer - Stocktwits
Verastem to Discontinue RAMP 203 Clinical Trial in Lung Cancer After Interim Data Read - marketscreener.com
Verastem stock falls after discontinuing KRAS G12C lung cancer trial By Investing.com - Investing.com Nigeria
Verastem (VSTM) Shifts Focus to Promising KRAS G12D Inhibitor in Cancer Treatment - GuruFocus
Verastem stock falls after discontinuing KRAS G12C lung cancer trial - Investing.com
Verastem discontinues KRAS G12C lung cancer trial to focus on G12D - Investing.com Canada
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
Calkins, Verastem CFO, sells $628 in shares - Investing.com India
Behavioral Patterns of VSTM and Institutional Flows - Stock Traders Daily
Verastem, Inc.'s (NASDAQ:VSTM) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump - simplywall.st
Is Verastem Inc a good long term investmentAI-Driven Market Analysis & Double Digit Wealth Tips - earlytimes.in
Will Verastem Inc. stock outperform Nasdaq indexJuly 2025 Final Week & Consistent Profit Trade Alerts - Улправда
Verastem (STU:2VS) EV-to-OCF : -3.85 (As of Dec. 20, 2025) - GuruFocus
Can Verastem Inc. stock surprise with earnings upsideQuarterly Portfolio Review & Low Risk Entry Point Guides - Улправда
Squarepoint Ops LLC Boosts Stake in Verastem, Inc. $VSTM - MarketBeat
Can Verastem Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target - MSN
Is Verastem Inc. stock vulnerable to regulatory risksQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Verastem streamlines leadership team amid strategic transition - MSN
Verastem, Inc. Announces Departure of Chief Operating Officer - TradingView — Track All Markets
Why Verastem Inc. stock could benefit from AI revolutionGDP Growth & Fast Exit Strategy with Risk Control - bolumsonucanavari.com
How Verastem Inc. (2VSA) stock moves in volatile trading sessionsJuly 2025 Patterns & Real-Time Buy Signal Alerts - Улправда
Will Verastem Inc. stock benefit from green energy trendsQuarterly Growth Report & Expert Approved Momentum Trade Ideas - Улправда
Insider Sell Alert: Brian Stuglik Sells Shares of Verastem Inc (VSTM) - GuruFocus
Dir Stuglik Surrenders 592 Of Verastem Inc [VSTM] - TradingView — Track All Markets
[Form 4] Verastem, Inc. Insider Trading Activity - Stock Titan
Verastem (VSTM) CEO sells 393 shares tied to RSU vesting - Stock Titan
Verastem (VSTM) director reports 283-share sale for RSU tax withholding - Stock Titan
RSI Check: Is Verastem Inc. stock a defensive play in 2025Earnings Overview Report & AI Enhanced Execution Alerts - ulpravda.ru
Verastem Oncology announces management changes - MSN
Guggenheim Keeps Their Buy Rating on Verastem (VSTM) - The Globe and Mail
Risk Report: Can Verastem Inc stock continue upward trend2025 Year in Review & Weekly Watchlist of Top Performers - moha.gov.vn
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):